title: Safety and immunogenicity of a Haemophilus influenzae type b conjugate vaccine in a high risk American Indian population.
abstract: The safety and immunogenicity of a Haemophilus influenzae type b polysaccharide conjugate vaccine linked to the outer membrane protein complex of Neisseria meningitidis (Hib-OMP) were evaluated among Apache and Navajo infants and children. One dose of the Hib-OMP was given to 42 children who were from 12 and 60 months of age. Ninety-two infants 6 to 8 weeks old were given one dose of Hib-OMP at the time of enrollment. A subsequent dose of the vaccine was given 2 months later and a third dose was offered between 12 and 15 months of age. All of the 12- to 60-month-old children achieved a protective antibody concentration (greater than 1 microgram/ml) 1 month postvaccination. Among the 6- to 8-week-old infants only 11% of the Apaches and 8% of Navajos had a protective anti-PRP antibody concentration prevaccination. One month post vaccination 68% of the Apaches and 69% of the Navajos had protective anti-PRP antibody concentrations. One month after the second immunization 67% of the Apaches and 75% of Navajos had protective anti-PRP concentrations. Among the infants that received the third (booster) immunization (N = 28) 74% had protective anti-PRP antibody titers just before the booster immunization. One month after the booster immunization all of the infants had protective concentrations of anti-PRP antibody. We conclude that the Hib-OMP is safe and highly immunogenic among Apache and Navajo infants and children.
authors.affiliation: Department of International Health, Johns Hopkins University School of Hygiene and Public Health, Baltimore, MD 21205.
authors.forename: M
authors.initials: M
authors.lastname: Santosham
authors.forename: J
authors.initials: J
authors.lastname: Hill
authors.forename: M
authors.initials: M
authors.lastname: Wolff
authors.forename: R
authors.initials: R
authors.lastname: Reid
authors.forename: L
authors.initials: L
authors.lastname: Lukacs
authors.forename: V
authors.initials: V
authors.lastname: Ahonkhai
mesh_terms: D000907:Antibodies, Bacterial / Q000032:analysis*; D001130:Arizona; D001425:Bacterial Outer Membrane Proteins / Q000009:adverse effects / Q000276:immunology*; D001428:Bacterial Vaccines / Q000009:adverse effects / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D006192:Haemophilus Infections / Q000517:prevention & control; D018073:Haemophilus Vaccines; D006193:Haemophilus influenzae / Q000276:immunology*; D006801:Humans; D007115:Immunization Schedule; D007198:Indians, North American; D007223:Infant; D011135:Polysaccharides, Bacterial / Q000009:adverse effects / Q000276:immunology*; D012306:Risk; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000009:adverse effects / Q000276:immunology
chemical_list: D000907:Antibodies, Bacterial; D001425:Bacterial Outer Membrane Proteins; D001428:Bacterial Vaccines; D018073:Haemophilus Vaccines; C061964:Haemophilus influenzae-type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine; D011135:Polysaccharides, Bacterial; D014614:Vaccines, Synthetic